Industry archivos | Page 2 of 2 | European Migraine & Headache Alliance

Galcanezumab-Cluster headache

Olivia Serratosa2018-05-22T10:32:30+00:0022/05/2018|Categories: Industry, News|Tags: Cluster Headache, migraine|

Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks In weekly clusters compared to placebo during the weeks one to three two-month double-blind treatment time shows. Weekly Cluster headache attacks A statistically significantly higher percentage of patients treated with galcanezumab also achieved a reduction in weekly cluster headache attacks by at least 50 percent compared to placebo in Week 3, the criterion of Secondary valuation. Security [...]

New Drug Offers Hope to Millions With Severe Migraines

Olivia Serratosa2018-05-18T11:28:13+00:0018/05/2018|Categories: Industry, News|Tags: CGRP, migraine|

The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a device similar to an insulin pen. The list price will be $6,900 a year, and Amgen said the drug will be available to patients within a week. Aimovig blocks a protein fragment, CGRP, that instigates and perpetuates migraines. Three other companies — Lilly, Teva and [...]

Potential source of gender differences in migraines

Olivia Serratosa2018-04-27T11:02:56+00:0027/04/2018|Categories: Industry, News|Tags: migraine|

Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone estrogen affect cells in the brain. Of the more than 38 million Americans who experience migraine headaches, 28 million are women. Compared to men, women also experience more frequent and severe migraines and don't respond as well to drug treatments. Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone [...]

Gallery

New measures to avoid valproate exposure in pregnancy

Olivia Serratosa2018-03-23T19:54:02+00:0023/03/2018|Categories: Industry|Tags: migraine|

The Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar disorder during pregnancy, and a ban on treating epilepsy during pregnancy unless there is no other effective treatment available. Further, the medicines must not be used in any woman or girl able to have children unless the conditions of a new pregnancy prevention programme are [...]

Gallery

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

Olivia Serratosa2017-08-10T15:32:49+00:0010/08/2017|Categories: Industry|Tags: migraine, Novartis|

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities and quality of life AMG 334 is being co-developed by Novartis and Amgen  Basel, 8 June 2016 – Novartis today announced positive first results from the global phase II 20120295 study, investigating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) [...]

Positive Phase III data for migraine drug Fremanezumab

Olivia Serratosa2017-07-01T08:27:04+00:0001/07/2017|Categories: Industry|

Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of at least moderate severity versus placebo (-2.5 days) during the 12 week period after first dose, for both monthly (-4.6 days p<0.0001) and quarterly (-4.3 days p<0.0001) dosing regimens. Similar to the Phase II trials, both patients that were on monotherapy and stable doses of [...]

Gallery

The results of greater occipital nerve block applied for migraine headache

Olivia Serratosa2017-04-10T14:25:45+00:0010/04/2017|Categories: Industry|

OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm inferior to the external occipital protuberance. The patients were evaluated in respect of VAS scores, attack frequency, attack duration and the need for analgesia before the procedure. These parameters were evaluated again at 1 week, 1 month and 3 months after the procedure. RESULTS: The [...]

Gallery

Disability & Catastrophizing In Chronic Migraine vs Temporomandibular Disorder

Olivia Serratosa2017-03-10T14:26:22+00:0010/03/2017|Categories: Industry, News|Tags: bibendum mauris, suscipit|

Patients with chronic migraine share features with individuals with temporomandibular disorders that include kinesiophobia and neck disability, according to a cross-sectional study recently published in Pain Medicine.1 A growing body of research indicates a number of shared features between chronic migraine and TMD. For example, patients with chronic migraine, but not headache-free individuals, commonly experience TMD symptoms such as tenderness in the masticatory muscles, and a type of secondary headache attributed to TMD is included in the International Classification of Headache Disorders 3 Beta.2-4 Patients with chronic migraine and TMD have both been found to have high levels of catastrophizing and kinesiophobia, [...]

EPF – European Patient Forum

European Union

World Health Organization

EHF- European Headache Federation

EMA- European Medicines Agency